BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Marzo V. The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
. Dialogues Clin Neurosci 2020;22:259-69. [PMID: 33162769 DOI: 10.31887/DCNS.2020.22.3/vdimarzo] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Falascina G, Bindels LB, Di Marzo V, Cutignano A. Validation of a fast and sensitive UPLC-MS/MS quantitative method for N-acyl taurine analysis in biological samples. J Pharm Biomed Anal 2023;226:115252. [PMID: 36657348 DOI: 10.1016/j.jpba.2023.115252] [Reference Citation Analysis]
2 Intranuovo F, Brunetti L, DelRe P, Mangiatordi GF, Stefanachi A, Laghezza A, Niso M, Leonetti F, Loiodice F, Ligresti A, Kostrzewa M, Brea J, Loza MI, Sotelo E, Saviano M, Colabufo NA, Riganti C, Abate C, Contino M. Development of N-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase. J Med Chem 2023;66:235-50. [PMID: 36542836 DOI: 10.1021/acs.jmedchem.2c01084] [Reference Citation Analysis]
3 Grabon W, Bodennec J, Rheims S, Belmeguenai A, Bezin L. Update on the controversial identity of cells expressing cnr2 gene in the nervous system. CNS Neurosci Ther 2023. [PMID: 36604187 DOI: 10.1111/cns.13977] [Reference Citation Analysis]
4 Crescente G, Minervini G, Spagnuolo C, Moccia S. Cannabis Bioactive Compound-Based Formulations: New Perspectives for the Management of Orofacial Pain. Molecules 2022;28. [PMID: 36615298 DOI: 10.3390/molecules28010106] [Reference Citation Analysis]
5 Schmiedhofer P, Vogel FD, Koniuszewski F, Ernst M. Cys-loop receptors on cannabinoids: All high? Front Physiol 2022;13. [DOI: 10.3389/fphys.2022.1044575] [Reference Citation Analysis]
6 Erridge S, Sodergren MH, Rucker JJ. Medical cannabis in autism spectrum disorder: a specialist perspective. British Journal of Neuroscience Nursing 2022;18:232-235. [DOI: 10.12968/bjnn.2022.18.5.232] [Reference Citation Analysis]
7 Erridge S, Kerr-Gaffney J, Holvey C, Coomber R, Barros DAR, Bhoskar U, Mwimba G, Praveen K, Symeon C, Sachdeva-Mohan S, Sodergren MH, Rucker JJ. Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry. Ther Adv Psychopharmacol 2022;12:20451253221116240. [PMID: 36159065 DOI: 10.1177/20451253221116240] [Reference Citation Analysis]
8 Puiu M, Bala C. Affinity Assays for Cannabinoids Detection: Are They Amenable to On-Site Screening? Biosensors 2022;12:608. [DOI: 10.3390/bios12080608] [Reference Citation Analysis]
9 Pedrazzi JFC, Ferreira FR, Silva-Amaral D, Lima DA, Hallak JEC, Zuardi AW, Del-Bel EA, Guimarães FS, Costa KCM, Campos AC, Crippa ACS, Crippa JAS. Cannabidiol for the treatment of autism spectrum disorder: hope or hype? Psychopharmacology (Berl) 2022. [PMID: 35904579 DOI: 10.1007/s00213-022-06196-4] [Reference Citation Analysis]
10 Ishiguro H, Kibret BG, Horiuchi Y, Onaivi ES. Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders. Front Psychiatry 2022;13:828895. [DOI: 10.3389/fpsyt.2022.828895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Pane K, Boccella S, Guida F, Franzese M, Maione S, Salvatore M. Role of gut microbiota in neuropathy and neuropathic pain states: A systematic preclinical review. Neurobiol Dis 2022;:105773. [PMID: 35623598 DOI: 10.1016/j.nbd.2022.105773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Kohansal F, Mobed A, Ansari R, Hasanzadeh M, Ahmadalipour A, Shadjou N. An innovative electrochemical immuno-platform towards ultra-sensitive monitoring of 2-arachidonoyl glycerol in samples from rats with sleep deprivation: bioanalysis of endogenous cannabinoids using biosensor technology. RSC Adv 2022;12:14154-66. [PMID: 35558840 DOI: 10.1039/d2ra00380e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kibret BG, Ishiguro H, Horiuchi Y, Onaivi ES. New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders. Int J Mol Sci 2022;23:975. [PMID: 35055161 DOI: 10.3390/ijms23020975] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
14 Sihag J, Di Marzo V. (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders. Lipids Health Dis 2022;21:9. [PMID: 35027074 DOI: 10.1186/s12944-021-01609-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
15 Hryhorowicz S, Kaczmarek-Ryś M, Zielińska A, Scott RJ, Słomski R, Pławski A. Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review. Front Immunol 2021;12:790803. [PMID: 35003109 DOI: 10.3389/fimmu.2021.790803] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
16 Hua D, Li S, Li S, Wang X, Wang Y, Xie Z, Zhao Y, Zhang J, Luo A. Gut Microbiome and Plasma Metabolome Signatures in Middle-Aged Mice With Cognitive Dysfunction Induced by Chronic Neuropathic Pain. Front Mol Neurosci 2022;14:806700. [DOI: 10.3389/fnmol.2021.806700] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Abolghasemi A, Manca C, Iannotti FA, Shen M, Leblanc N, Lacroix S, Martin C, Flamand N, Di Marzo V, Silvestri C. Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis. Int J Mol Sci 2021;22:12361. [PMID: 34830242 DOI: 10.3390/ijms222212361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Suriano F, Manca C, Flamand N, Depommier C, Van Hul M, Delzenne NM, Silvestri C, Cani PD, Di Marzo V. Exploring the endocannabinoidome in genetically obese (ob/ob) and diabetic (db/db) mice: Links with inflammation and gut microbiota. Biochim Biophys Acta Mol Cell Biol Lipids 2022;1867:159056. [PMID: 34606993 DOI: 10.1016/j.bbalip.2021.159056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Bisogno T, Lauritano A, Piscitelli F. The Endocannabinoid System: A Bridge between Alzheimer's Disease and Gut Microbiota. Life (Basel) 2021;11:934. [PMID: 34575083 DOI: 10.3390/life11090934] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
20 Kwan Cheung KA, Mitchell MD, Heussler HS. Cannabidiol and Neurodevelopmental Disorders in Children. Front Psychiatry 2021;12:643442. [PMID: 34093265 DOI: 10.3389/fpsyt.2021.643442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
21 Depommier C, Flamand N, Pelicaen R, Maiter D, Thissen JP, Loumaye A, Hermans MP, Everard A, Delzenne NM, Di Marzo V, Cani PD. Linking the Endocannabinoidome with Specific Metabolic Parameters in an Overweight and Insulin-Resistant Population: From Multivariate Exploratory Analysis to Univariate Analysis and Construction of Predictive Models. Cells 2021;10:E71. [PMID: 33466285 DOI: 10.3390/cells10010071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]